Laboratory Treated T-Cells in Treating Patients with Recurrent CD19+ Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Receiving Ibrutinib

Inclusion Criteria

• Documented CD19+ chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
• Successful test expansion -cells
• Patients must have failed at least 1 prior regimen before ibrutinib (not including single agent rituximab or single agent corticosteroids) * Note: any relapse after prior autologous stem cell transplantation (SCT) will make the patient eligible regardless of other prior therapy
• Patients must be currently receiving ibrutinib for at least 6 months prior to enrollment in the study and: * Not experiencing any >= grade 2 non-hematologic ibrutinib-related toxicity * The best response to ibrutinib therapy must not have exceeded partial response or stable disease (i.e. no complete response [CR] or complete response with incomplete marrow recovery [CRi]) * Note: patients carrying a deletion at chromosome 17p (i.e. deletion [del][17p]), and/or tumor protein (TP)53, Bruton's tyrosine kinase (BTK), and at the phospholipase C, gamma 2 (PLCgamma 2) loci mutations, will be eligible if they are receiving frontline therapy with ibrutinib
• Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
• Creatinine < 1.6 mg/dl
• Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) < 3x upper limit of normal
• Total bilirubin < 2.0 mg/dl with the exception of patients with Gilbert syndrome; patients with Gilbert syndrome may be included if their total bilirubin is >= 3.0 x upper limit of normal (ULN) and direct bilirubin =< 1.5 x ULN
• Patients with relapsed disease after prior allogeneic SCT (myeloablative or nonmyeloablative) will be eligible if they meet all other inclusion criteria and: * Have no active graft versus host disease (GVHD) and require no immunosuppression * Are more than 6 months from transplant
• No contraindications for leukapheresis
• Left ventricular ejection fraction >= 40%
• Gives voluntary informed consent
• Subjects of reproductive potential must agree to use acceptable birth control methods

Exclusion Criteria

• CLL patients with known or suspected transformed disease (i.e. Richter’s transformation) * Note: biopsy proven absence of transformation is not required
• Pregnant or lactating women; female study participants of reproductive potential must have a negative serum or urine pregnancy test performed within 48 hours before infusion
• Uncontrolled active infection
• Active hepatitis B or hepatitis C infection
• Concurrent use of systemic steroids or chronic use of immunosuppressant medications; recent or current use of inhaled steroids is not exclusionary
• Any uncontrolled active medical disorder that would preclude participation as outlined
• Human immunodeficiency virus (HIV) infection
• Patients with active central nervous system (CNS) involvement with malignancy; patients with prior CNS disease that has been effectively treated will be eligible providing treatment was > 4 weeks before enrollment
• Class III/IV cardiovascular disability according to the New York Heart Association Classification
• Subjects with clinically apparent arrhythmia or arrhythmias who are not stable on medical management within two weeks of enrollment
• Patients with a known history or prior diagnosis of optic neuritis or other immunologic or inflammatory disease affecting the central nervous system